FDA clears ArteraAI Breast for breast cancer risk stratificationFDA clears ArteraAI Breast for breast cancer risk stratification
The U.S. Food and Drug Administration has cleared ArteraAI Breast for use in patients with early-stage, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer.
STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Good morning health tech readers! Today, my colleagues Isabella Cueto and Lev Facher are launching the Deadliest Drug, a series on the often ignored Read More
FDA Approves GLP-1 Obesity Pill Without Food or Water RestrictionsFDA Approves GLP-1 Obesity Pill Without Food or Water Restrictions
The US Food and Drug Administration (FDA) approved the oral glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron, marketed as Foundayo, for daily use in people with overweight or obesity. Unlike other oral GLP-1 drugs, orforglipron can be taken any time of day without food or water restrictions. The US Food and Drug Administration (FDA) approved the Read More
Screening for Breast CancerScreening for Breast Cancer
To the Editor Individualized, risk-based approaches to cancer screening aspire to resolve shortcomings of the traditional population- and age-based approach. Yet, until now, reliable evidence was not available to appropriately evaluate whether tailoring breast cancer screening according to cancer risk can increase benefits and reduce harms compared with the current approach. We therefore commend the WISDOM (Women Informed to Screen Depending on Measures of Risk) study, which provided crucial insights into risk-based breast cancer screening’s effects. However, we are concerned about the limited potential of risk-based screening for reducing harms, notably overdiagnosis, which involves diagnosis of cancers that do not progress to become symptomatic or harmful.
Screening for Breast Cancer—ReplyScreening for Breast Cancer—Reply
In Reply We appreciate that a one-size-fits-all approach to breast cancer screening is increasingly anachronistic, given the heterogeneity of breast cancer and the imbalanced distribution of risk factors across the population. The WISDOM results demonstrated that a risk-based strategy can stratify population risk, facilitating personalized screening and prevention strategies while preserving safety.
Stage IV Breast Cancer Incidence and Survival, 2010-2021Stage IV Breast Cancer Incidence and Survival, 2010-2021
This cohort study assesses the changes in the incidence, percentage, and survival of people diagnosed with de novo stage IV breast cancer from 2010 through 2021.
Screening for Breast CancerScreening for Breast Cancer
To the Editor The prevailing one-size-fits-all paradigm of breast cancer screening—largely based on age and fixed intervals—was designed during an era with limited risk stratification, few prevention pathways, and limited ability to tailor imaging intensity. Pragmatic randomized clinical trials, such as WISDOM, are therefore essential to generate evidence with a prevention strategy that can reallocate resources from women at lower risk of breast cancer to those at higher risk.
Rising Incidence of Stage IV Breast CancerRising Incidence of Stage IV Breast Cancer
Oncology
More Evidence that GLP-1s May Reduce Risk of Vision-Robbing Eye DiseasesMore Evidence that GLP-1s May Reduce Risk of Vision-Robbing Eye Diseases
(MedPage Today) — Patients taking GLP-1 receptor agonists (GLP-1RAs) had a lower likelihood of developing age-related macular degeneration (AMD) compared with patients using other glucose-lowering medications or lipid-lowering drugs, a large retrospective… (MedPage Today) — Patients taking GLP-1 receptor agonists (GLP-1RAs) had a lower likelihood of developing age-related macular degeneration (AMD) compared with patients Read More
What Do Patients Want Doctors to Know About Breast Cancer Recurrence?What Do Patients Want Doctors to Know About Breast Cancer Recurrence?
(MedPage Today) — This article includes a first-person perspective from early breast cancer patient Lina. Lina was compensated for her time by Novartis.
Some patients with hormone receptor (HR)-positive, human epidermal growth factor receptor…